

## Supporting Information

### Biomimetic enzyme barrier for preventing intestine-derived LPS induced diseases

Cheng Zhao<sup>1,2,3</sup>, Xiaoming Kao<sup>1</sup>, Zhiwei Wang<sup>1,2</sup>, Qinjie Liu<sup>1,2</sup>, Jie Wu<sup>1,2</sup>, Qiongyuan  
Hu<sup>1,2</sup>, Xiuwen Wu<sup>\*,1,2</sup>, Jianan Ren<sup>\*,1,2</sup>


<sup>1</sup>Research institute of general surgery, Jinling Hospital, Medical School of Nanjing  
University, Nanjing 210002, China

<sup>2</sup>Lab for Trauma and Surgical Infection, Jinling Hospital, Nanjing, China


<sup>3</sup>Department of Endocrinology, Xiangya Shenzhen Endocrinology and Metabolism  
Center, the First Affiliated Hospital of Shenzhen University, Shenzhen, People's  
Republic of China

Email: lygwxw@163.com; jiananr@gmail.com


Figures




**Figure S1.** Regulating the diameters of the microcapsules through changing variables. The diameter decreased with increased  $U$ , decreased  $d$ , decreased  $F_{\text{outer}}$  and  $F_{\text{inner}}$ .



**Figure S2.** Cumulative drug release of microcapsules in pH 1.5 (A) and pH 7.4 (B).



**Figure S3.** The concentration of LPS of different groups in A) intestine, B) heart, C) liver, D) spleen, E) lung and F) kidney.



**Figure S4.** The inflammation level of different groups in A-C) intestine and D-F) spleen.